DNMT1 and neoplasm: Silencing of tumor suppressors and DNA repair enzymes by aberrant hypermethylation is seen in many cancers, and the DNMT1 inhibitors azacitidine and decitabine are used to exploit this fact in hematologic cancers to demethylate suppressed promoters, thereby reactivating silenced tumor suppressors [28].